S. G. Deeks, C. M. Kitchen, L. Liu, H. Guo, R. Gascon, A. B. Narváez, P. Hunt, J. N. Martin, J. O. Kahn, J. Levy, M. S. McGrath and F. M. Hecht, “Immune Activation Set Point during Early HIV Infection Predicts Subsequent CD4+ T-Cell Changes Independent of Viral Load,” Blood, Vol. 104, No. 4, 2004, pp. 942-927. doi:10.1182/blood-2003-09-3333

has been cited by the following article:

• TITLE: Immune Activation in HIV-Infected Patients Treated with Different ARV Regimens

  AUTHORS: Alessia Uglietti, Sergio Lo Caputo, Marinella Lauriola, Michele De Gennaro, Elisabetta Chiesa, Massimo Coen, Roberta Terzi, Dorothy H. Bray, Renato Maserati, Daria Trabattoni, Mario Clerici

  KEYWORDS: HIV; Immune Activation; Antiretroviral Therapy

  JOURNAL NAME: World Journal of AIDS, Vol.2 No.2, June 15, 2012

  ABSTRACT: Objectives: To evaluate the effects of starting therapy with either Truvada (TVD) or Combivir (CBV) in combination with Efavirenz (EFV) or a boosted Protease Inhibitor (LPV/r, ATV/r, fAPV/r and SQV/r) on clinical, immunological, and virological parameters in HIV-infected antiretroviral (ARV) naive patients. Methods: Twenty-seven patients were prospectively enrolled and received TVD-EFV, 32 TVD-PI/r, 24 CBV-EFV, and 23 CBV-PI/r. Immunovirological analyses were performed at baseline and after 3, 6, 9 and 12 months after initiation of therapy; a full set of data is available for 51 patients. Results: Median CD4+ cell counts and HIV-RNA plasma viremia were comparable in the four groups of patients (TVD-EFV, TVD-PI/r, CBV-EFV, CBV-PI/r) at baseline. At month 12 HIV RNA plasma viremia was